Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.29 USD
Change Today 0.00 / 0.00%
Volume 0.0
RVALL On Other Exchanges
As of 4:30 PM 12/12/14 All times are local (Market data is delayed by at least 15 minutes).

reva medical inc - cdi (RVALL) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/24/14 - $0.30
52 Week Low
09/15/14 - $0.13
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for REVA MEDICAL INC - CDI (RVALL)

Related News

No related news articles were found.

reva medical inc - cdi (RVALL) Related Businessweek News

No Related Businessweek News Found

reva medical inc - cdi (RVALL) Details

REVA Medical, Inc., a development stage medical device company, focuses on the commercialization of minimally invasive medical devices for the treatment of coronary artery disease in the human heart. It is developing and testing a bioresorbable stent to treat vascular disease in humans under the Fantom scaffolds name. The company was formerly known as MD3, Inc. and changed its name to REVA Medical, Inc. in March 2002. REVA Medical, Inc. was founded in 1998 and is headquartered in San Diego, California.

46 Employees
Last Reported Date: 03/30/15
Founded in 1998

reva medical inc - cdi (RVALL) Top Compensated Officers

Co-founder, Chairman and Chief Executive Offi...
Total Annual Compensation: $359.7K
President and Chief Operating Officer
Total Annual Compensation: $340.8K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $275.2K
Senior Vice President of Clinical & Regulator...
Total Annual Compensation: $260.9K
Senior Vice President of Product Development
Total Annual Compensation: $254.0K
Compensation as of Fiscal Year 2013.

reva medical inc - cdi (RVALL) Key Developments

REVA Medical, Inc. Reports Audited Consolidated Earnings Results for the Full Year Ended December 31, 2014

REVA Medical, Inc. reported audited consolidated earnings results for the full year ended December 31, 2014. For the year, the company reported loss from operations of $21,963,000 compared to loss from operations of $27,943,000 for the same period a year ago. Net loss and comprehensive loss was $51,037,000 or $1.53 per basic and diluted share compared to $27,922,000 or $0.84 per basic and diluted share last year. Net cash used for operating activities was $17,930,000 compared to $21,943,000 last year. Purchases of property and equipment were $541,000 compared to $1,466,000 last year.

REVA Medical, Inc. Appoints Scott Huennekens as Non-Executive Director

REVA Medical, Inc. announced that Scott Huennekens, a recognized business executive in the medical device industry, has been appointed to its Board of Directors as a non-executive director. Mr. Huennekens currently serves on the boards of EndoChoice, Sonendo, Scripps Translational Science Institute, and the Medical Device Manufacturers Association (MDMA).

REVA Medical, Inc. Announces the Initiation of Patient Enrollment in the FANTOM II Clinical Trial of its Fantom™ Sirolimus-eluting bioresorbable scaffold

REVA Medical, Inc. announced the initiation of patient enrollment in the FANTOM II clinical trial of its Fantom™ sirolimus-eluting bioresorbable scaffold. The Fantom scaffold, made from REVA’s advanced proprietary polymer, is designed to allow the restoration of blood flow in patients being treated for coronary artery disease, then resorb from the body over time. The FANTOM II trial will enroll patients at multiple clinical sites in eight countries. Data from up to 110 patients in this trial is intended to be used in a European CE Mark application which is expected to occur by mid-2016. The live implant of the Fantom scaffold involved a patient that presented with a 70% blockage of the left anterior descending artery of the heart. The Fantom scaffold was clearly visible during the procedure, easily delivered to the location of the blockage, and expanded to its intended diameter in a standard clinical procedure to restore blood flow.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RVALL:US $0.29 USD 0.00

RVALL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RVALL.
View Industry Companies

Industry Analysis


Industry Average

Valuation RVALL Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REVA MEDICAL INC - CDI, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at